Innovation is the lifeblood of 21st century biotechnology. It is more than just invention; it is the rational and creative application of technology to solve problems. Nowhere is innovation more needed than in the field of medicine. Advances in immunology have powered new therapies that could change the way that we treat cancers and other chronic diseases—with implications for millions of lives. One of the critical problems, especially in the field of immunotherapy, is the huge number of therapies that are potentially effective, but can never be used on patients because they are too toxic. The vast armamentarium of potential therapies that are left sitting on the shelf should result in moral outrage for the cancer research community. The central challenge is lack of a delivery platform capable of delivering immunostimulation to the tumor microenvironment without systemic distribution. Many immunotherapies stimulate uncontrolled broad immune reactions that can be life-threatening. If these therapies could be combined with a delivery vehicle capable of limiting them to the local tumor site, the might of the human immune system could be focused to eliminate malignant disease, with dramatically reduced systemic side effects. What is needed now is true innovation- the development of new platforms that are capable of realizing the dividends of decades of immunologic research to finally put these therapies into the hands of physicians and patients.
The genesis of NanoRed, LLC is tied directly to answering the central challenge of drug and immunotherapy delivery in cancer. We believe that no physician and no patient should ever have to choose between doing nothing or choosing a therapy that could have lifelong toxicities. We believe that no patient should be denied the potentially life-saving benefits of the vast armamentarium of novel cancer therapeutics for lack of a means to safely deliver them. These two guiding principles represent the core of NanoRed. Our bedrock is patients and their families, grounded in the application of excellent science.
We believe in innovation, which means using new and creative ways to make a difference in the lives of patients. The Nanotechnology Startup Challenge in Cancer shares our vision. Through the training and resources received here, NanoRed is ready to begin the journey of deploying a novel delivery platform for cancer drugs. The defined preclinical proof-of-concept for this precision delivery system in animals has laid the groundwork for NanoRed to move this technology to the clinic quickly and aggressively. Our engineered liposomes release their contents specifically within tumors after stimulation with the right infrared wavelength. Infrared gives us the advantage of deeper tissue penetration, enabling us to target sarcomas and soft tissue cancers that other delivery platforms cannot reach. Building on the successes of this technology to date, NanoRed has assembled a dedicated team and built collaborations and relationships with key stakeholders to enable rapid testing of this platform as a means to deliver immunotherapeutics directly to sarcomas and soft tissue cancers. This proof-of-concept in human clinical trials will significantly de-risk the technology and pave the way for our drug delivery platform to become the next generation standard of care, providing new hope to patients.
The genesis of NanoRed, LLC is tied directly to answering the central challenge of drug and immunotherapy delivery in cancer. We believe that no physician and no patient should ever have to choose between doing nothing or choosing a therapy that could have lifelong toxicities. We believe that no patient should be denied the potentially life-saving benefits of the vast armamentarium of novel cancer therapeutics for lack of a means to safely deliver them. These two guiding principles represent the core of NanoRed. Our bedrock is patients and their families, grounded in the application of excellent science.
We believe in innovation, which means using new and creative ways to make a difference in the lives of patients. The Nanotechnology Startup Challenge in Cancer shares our vision. Through the training and resources received here, NanoRed is ready to begin the journey of deploying a novel delivery platform for cancer drugs. The defined preclinical proof-of-concept for this precision delivery system in animals has laid the groundwork for NanoRed to move this technology to the clinic quickly and aggressively. Our engineered liposomes release their contents specifically within tumors after stimulation with the right infrared wavelength. Infrared gives us the advantage of deeper tissue penetration, enabling us to target sarcomas and soft tissue cancers that other delivery platforms cannot reach. Building on the successes of this technology to date, NanoRed has assembled a dedicated team and built collaborations and relationships with key stakeholders to enable rapid testing of this platform as a means to deliver immunotherapeutics directly to sarcomas and soft tissue cancers. This proof-of-concept in human clinical trials will significantly de-risk the technology and pave the way for our drug delivery platform to become the next generation standard of care, providing new hope to patients.
RSS Feed
